細胞名稱

人肝內(nèi)膽管癌細胞HuCCT-1

貨物編碼

BFN60808823

產(chǎn)品規(guī)格

T25培養(yǎng)瓶x1

1.5ml凍存管x2

細胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研   3類

培養(yǎng)體系

90%DMEM+10%FBS+1%三抗

培養(yǎng)溫度

37℃

二氧化碳濃度

5%

簡介

人肝內(nèi)膽管癌細胞HuCCT-1取自56歲男性供體。該細胞源于JCRB

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: TCGA-110-CL cell line panel.

Doubling time: ~55 hours (at 10th passage in RPMI + 10% FBS), ~74 hours (at 25th passage in RPMI + 0.2% LA) (PubMed=2544546).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

基因突變

Heterozygous for KRAS p.Gly12Asp (c.35G>A) (ClinVar=VCV000012582) (CCLE; Cosmic-CLP).

Heterozygous for MSH6 p.Lys1358fs*2 (c.4071_4072insGATT) (CCLE; Cosmic-CLP).

Homozygous for TP53 p.Arg175His (c.524G>A) (ClinVar=VCV000012374) (CCLE; Cosmic-CLP).

HLA信息

/

STR信息

Amelogenin        X,Y

CSF1PO        11,12

D2S1338        17,18

D3S1358        15

D5S818        12,13

D7S820        10,11

D8S1179        10

D13S317        11,13

D16S539        11,12 (Cosmic-CLP; JCRB; RCB; TKG)

9,11,12 (PubMed=25877200)

D18S51        13

D19S433        13

D21S11        31

FGA        20,23

Penta D        10

Penta E        15,18

TH01        7,10

TPOX        8

vWA        18

參考文獻

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31077409; DOI=10.1002/hep.30704

Sittithumcharee G., Suppramote O., Vaeteewoottacharn K., Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M., Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K., Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P., Pairojkul C., Wongkham S., Sampattavanich S., Okada S., Jirawatnotai S.

Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity.

Hepatology 70:1614-1630(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2

Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

Nat. Commun. 10:3574-3574(2019)